Anzeige
Mehr »
Login
Mittwoch, 13.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Wir entschlüsseln die 55 $ pro Aktie Clean-Energy-Chance für SIE!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
348 Leser
Artikel bewerten:
(2)

R3 and Quant support the publication of UK Finance's UK Regulated Liability Network (RLN) experimentation phase report

Finanznachrichten News

R3 and Quant, alongside DXC Technology and Coadjute are technology partners to the UK RLN

LONDON, Sept. 17, 2024, the infrastructure platform building digital solutions for financial markets, and Quant, the digital finance pioneer, announce the publication of the results of UK Finance's UK Regulated Liability Network. The reportwhich follows work with UK Finance with eleven of its members1 and partners2 on a new experimentation phase. This is a new type of financial market infrastructure that can deliver new capabilities for payments and settlement, including tokenisation and programmability.

R3 and Quant were selectedby the UK RLN, alongside DXC Technology and Coadjute, as technology partners in exploring a number of use cases and in particular the technology workstream which delivered a multi-issuer DLT-based Tokenisation Platform, a comprehensive API for interaction with all forms of money, and an Orchestration Layer. Implementation of the Orchestration Layer seamlessly connected the Tokenisation Platform to different ledgers and integrated with existing systems (e.g. Open Banking, Project Rosalind, and simulated RTGS).

Together with other participants, R3 and Quant reviewed and worked on various technical, legal and business case questions surrounding the development of an RLN and the main conclusions are:

  • Such a platform, in collaboration with other important initiatives such as Open Banking, could deliver economic value and support innovation in the market.
  • New functionality, such as programmable payments and locking/unlocking of funds, could be delivered across a range of use cases.
  • It could provide new and innovative firms with a single, common point of access to enable them to interface with established institutions, and enhanced payment and settlement systems.
  • The legal and regulatory framework of the UK is sufficiently flexible to support the implementation of an RLN.

R3 has brought its ability to deliver complex pioneering projects for regulated markets whilst providing the critical distributed ledger capability, via Corda, its leading open permissioned DLT platform, powering the tokenisation of assets and currencies connecting global markets. Quant enabled programmability and interoperability across different forms of money by delivering the orchestration and API layer to the project with its Overledger platform.

Jana Mackintosh, Managing Director of Payments, Innovation and Operational Resilience at UK Finance, said:

"Every year, over £11 trillion worth of payments are processed in the UK, powering the economy. The success of the RLN experiment shows the potential of technology to transform the customer experience and deliver economic value and benefits for society.

"The Experimentation Phase demonstrated the power of industry collaboration to deliver a platform for innovation in the UK. The private sector wants to invest in the future of commercial bank money but needs a partnership with regulators to do so."

Kate Karimson, R3 Chief Commercial Officer, said:

"We're proud to be a part of this pioneering effort where the UK finance industry has operated across retail, wholesale, technology and legal workstreams in a collaborative manner. R3 is committed to progressing financial markets and to enabling an open, trusted and advanced digital economy. The success of the RLN experimentation phase and the publication of a roadmap for the UK economy to harness the potential for the benefits of tokenisation demonstrates our advanced technology implementation capability."

Gilbert Verdian, Founder and CEO at Quant, said:

"The RLN isn't just about enhancing the efficiency of our current payment infrastructure; it's about creating different forms of money that will transform the way value and assets are moved and managed. Programmability is at the heart of the transition to digital finance. As the project has proven, programmability brings new functionality across payments and settlement that are inconceivable under the current system. Implementing programmability will be key to cementing the UK's leadership position in digital finance and futureproofing our capital markets for the decades to come. As the digital economy evolves, we're excited to continue working with other project participants in delivering further innovation across payments."

Media enquiries

Eterna Partners for R3

R3@eternapartners.com

Aspectus for Quant

Quant@AspectusGroup.com


1 Barclays, Citi, HSBC, Lloyds Banking Group, Mastercard, NatWest, Nationwide, Santander, Standard Chartered, Virgin Money and VISA.
2 EY and Linklaters and a technology team of R3, Quant, DXC and Coadjute.


© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.